Cite
Wang XJ, Gong P, Zhou C, et al. Liraglutide reduces attenuation coefficient as a measure of hepatic steatosis during 16 weeks' treatment in nondiabetic obese patients: A pilot trial. JGH Open. 2020;5(2):193-198doi: 10.1002/jgh3.12464.
Wang, X. J., Gong, P., Zhou, C., Huang, C., Lok, U. W., Tang, S., Taylor, A., Eckert, D., Chen, S., & Camilleri, M. (2021). Liraglutide reduces attenuation coefficient as a measure of hepatic steatosis during 16 weeks' treatment in nondiabetic obese patients: A pilot trial. JGH open : an open access journal of gastroenterology and hepatology, 5(2), 193-198. https://doi.org/10.1002/jgh3.12464
Wang, Xiao Jing, et al. "Liraglutide reduces attenuation coefficient as a measure of hepatic steatosis during 16 weeks' treatment in nondiabetic obese patients: A pilot trial." JGH open : an open access journal of gastroenterology and hepatology vol. 5,2 (2021): 193-198. doi: https://doi.org/10.1002/jgh3.12464
Wang XJ, Gong P, Zhou C, Huang C, Lok UW, Tang S, Taylor A, Eckert D, Chen S, Camilleri M. Liraglutide reduces attenuation coefficient as a measure of hepatic steatosis during 16 weeks' treatment in nondiabetic obese patients: A pilot trial. JGH Open. 2020 Dec 30;5(2):193-198. doi: 10.1002/jgh3.12464. eCollection 2021 Feb. PMID: 33553655; PMCID: PMC7857298.
Copy
Download .nbib